Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854737 · ClinicalTrials.gov registry record · Phase 2
Cytidine and Omega-3 Fatty Acids in Bipolar Disorder
A Phase 2 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00854737: Completed Phase 2 study, sponsored by Mclean Hospital.
NCT00854737 is a Phase 2 study that has completed, run by Mclean Hospital. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00854737, a Phase 2 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo supplementation.
Interventions
- DRUG placebo
- DIETARY_SUPPLEMENT cytidine
- DIETARY_SUPPLEMENT omega-3 fatty acids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT00854737 record still lists
NCT00854737 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00854737 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00854737 about?
NCT00854737 is a clinical study titled "Cytidine and Omega-3 Fatty Acids in Bipolar Disorder". The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 r...
What is the current status of trial NCT00854737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2004-07. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00854737?
The interventions under investigation include: placebo (DRUG), cytidine (DIETARY_SUPPLEMENT), omega-3 fatty acids (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00854737?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00854737's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia